Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome.
暂无分享,去创建一个
Kevin D Costa | Roger J Hajjar | K. Costa | R. Hajjar | T. Hampton | Francesco Ramirez | L. Carta | F. Ramirez | Thomas G Hampton | E. Chemaly | Luca Carta | J. Cook | Peter Yurchenco | Elie R Chemaly | P. Yurchenco | Jason R Cook | Ludovic Bénard | Emily Chiu | Satish K Rao | L. Bénard | Satish Rao | E. Chiu
[1] Patrick Segers,et al. Primary impairment of left ventricular function in Marfan syndrome. , 2006, International journal of cardiology.
[2] P. Robinson,et al. Tissue Doppler imaging identifies myocardial dysfunction in adults with marfan syndrome , 2007, Clinical Cardiology.
[3] A. Zwinderman,et al. Intrinsic biventricular dysfunction in Marfan syndrome , 2011, Heart.
[4] L. Sakai,et al. Biogenesis and function of fibrillin assemblies , 2009, Cell and Tissue Research.
[5] H. S. Kim,et al. Genetic control of blood pressure and the angiotensinogen locus. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[6] S. Colan,et al. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. , 2007, American heart journal.
[7] J. Seidman,et al. The Genetic Basis for Cardiomyopathy from Mutation Identification to Mechanistic Paradigms , 2001, Cell.
[8] K. Eagle. Rationale and design of the National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (GenTAC). , 2009, American heart journal.
[9] F. Ramirez,et al. Generation of Fbn1 conditional null mice implicates the extracellular microfibrils in osteoprogenitor recruitment , 2012, Genesis.
[10] H. Dietz,et al. p38 MAPK Is an Early Determinant of Promiscuous Smad2/3 Signaling in the Aortas of Fibrillin-1 (Fbn1)-null Mice* , 2009, Journal of Biological Chemistry.
[11] L. Hunyady,et al. Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[12] M. Entman,et al. Angiotensin II Blockade Reverses Myocardial Fibrosis in a Transgenic Mouse Model of Human Hypertrophic Cardiomyopathy , 2001, Circulation.
[13] T. Doetschman,et al. TGF-β1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II , 2002 .
[14] D. Judge,et al. Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic states , 2007, Nature Medicine.
[15] L. Tavazzi,et al. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations , 2009, Journal of cardiovascular medicine.
[16] B. McCrindle,et al. General cardiology: abstractLong-term outcome in patients with Marfan syndrome: is aortic dissection the only cause of sudden death?☆ , 2003 .
[17] Samarjit Patnaik,et al. Noncanonical TGFβ Signaling Contributes to Aortic Aneurysm Progression in Marfan Syndrome Mice , 2011, Science.
[18] Kevin D Costa,et al. Cross-bridge cycling gives rise to spatiotemporal heterogeneity of dynamic subcellular mechanics in cardiac myocytes probed with atomic force microscopy. , 2010, American journal of physiology. Heart and circulatory physiology.
[19] J. Coselli,et al. Marfan syndrome. Long-term survival and complications after aortic aneurysm repair. , 1995, Circulation.
[20] D. Rifkin,et al. Extracellular microfibrils: contextual platforms for TGFbeta and BMP signaling. , 2009, Current opinion in cell biology.
[21] A. Zwinderman,et al. Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial , 2010, Trials.
[22] Pál Pacher,et al. Measurement of cardiac function using pressure–volume conductance catheter technique in mice and rats , 2008, Nature Protocols.
[23] P. Hekali,et al. Left ventricular function in children with the Marfan syndrome. , 1994, European heart journal.
[24] Masashi Takahashi,et al. Myocardial involvement in the Marfan syndrome. , 1985, Japanese heart journal.
[25] D. Kass,et al. Thrombospondin-4 Is Required for Stretch-Mediated Contractility Augmentation in Cardiac Muscle , 2011, Circulation research.
[26] Joyce Wong,et al. Evidence for Marfan cardiomyopathy , 2010, European journal of heart failure.
[27] K. Vranizan,et al. Conditional expression of a Gi-coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[28] J. Stockman,et al. Noncanonical TGFβ Signaling Contributes to Aortic Aneurysm Progression in Marfan Syndrome Mice , 2012 .
[29] Henk A Marquering,et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. , 2013, European heart journal.
[30] John Camm,et al. Early impairment of left ventricular long-axis systolic function demonstrated by reduced atrioventricular plane displacement in patients with Marfan syndrome. , 2008, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.
[31] J. Molkentin,et al. Signaling effectors underlying pathologic growth and remodeling of the heart. , 2013, The Journal of clinical investigation.
[32] H. Dietz,et al. Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[33] T. Geva,et al. Two-dimensional and Doppler echocardiographic and pathologic characteristics of the infantile Marfan syndrome. , 1990, The American journal of cardiology.
[34] P. Robinson,et al. Novel exon skipping mutation in the fibrillin‐1 gene: Two ‘hot spots’ for the neonatal Marfan syndrome , 1999, Clinical genetics.
[35] B. Das,et al. Left Ventricular Diastolic Dysfunction in Children and Young Adults with Marfan Syndrome , 2006, Pediatric Cardiology.
[36] D. Judge,et al. TGF-β–dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome , 2004 .
[37] J. Lincoln,et al. Reduced Sox9 Function Promotes Heart Valve Calcification Phenotypes In Vivo , 2010, Circulation research.
[38] Y C Fung,et al. Residual strain in rat left ventricle. , 1990, Circulation research.
[39] K. Rakesh,et al. β-Arrestin–Biased Agonism of the Angiotensin Receptor Induced by Mechanical Stress , 2010, Science Signaling.
[40] A. Erkol,et al. Dilated cardiomyopathy in a patient with Marfan syndrome accompanied by chronic type A aortic dissection and right atrial thrombus. , 2010, Internal medicine.
[41] A. McMahon,et al. Fate of the mammalian cranial neural crest during tooth and mandibular morphogenesis. , 2000, Development.
[42] Jessica Geubtner,et al. Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. , 2004, The Journal of clinical investigation.
[43] D. Ingber,et al. Extracellular matrix, mechanotransduction and structural hierarchies in heart tissue engineering , 2007, Philosophical Transactions of the Royal Society B: Biological Sciences.
[44] C. Pham,et al. Modulation of integrins and integrin signaling molecules in the pressure-loaded murine ventricle , 2002, Histochemistry and Cell Biology.
[45] R. Pyeritz. The Marfan syndrome. , 1986, American family physician.
[46] N. Koitabashi,et al. Increased Connective Tissue Growth Factor Relative to Brain Natriuretic Peptide as a Determinant of Myocardial Fibrosis , 2007, Hypertension.
[47] L. Leinwand,et al. The cell biology of disease Cellular mechanisms of cardiomyopathy , 2022 .
[48] I. Komuro,et al. Conformational switch of angiotensin II type 1 receptor underlying mechanical stress‐induced activation , 2008, EMBO reports.
[49] D. Keene,et al. Fibrillins 1 and 2 Perform Partially Overlapping Functions during Aortic Development* , 2006, Journal of Biological Chemistry.
[50] D. Driscoll,et al. Left ventricular function in the Marfan syndrome without significant valvular regurgitation. , 2003, American Journal of Cardiology.
[51] John A Pearce,et al. Dynamic correction for parallel conductance, GP, and gain factor, alpha, in invasive murine left ventricular volume measurements. , 2009, Journal of applied physiology.
[52] D. Judge,et al. Angiotensin II Type 2 Receptor Signaling Attenuates Aortic Aneurysm in Mice Through ERK Antagonism , 2011, Science.
[53] L. Leinwand,et al. Cellular mechanisms of cardiomyopathy , 2011, The Journal of cell biology.
[54] J. Timmermans,et al. Evaluation of left ventricular dimensions and function in Marfan's syndrome without significant valvular regurgitation. , 2005, The American journal of cardiology.
[55] W. Pu,et al. Dilated cardiomyopathy resulting from high-level myocardial expression of Cre-recombinase. , 2006, Journal of cardiac failure.
[56] R. Behringer,et al. Endocardial cushion and myocardial defects after cardiac myocyte-specific conditional deletion of the bone morphogenetic protein receptor ALK3 , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[57] D. M. Foster,et al. Integrins and proximal signaling mechanisms in cardiovascular disease. , 2009, Frontiers in bioscience.
[58] Marc K. Halushka,et al. Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome , 2006, Science.
[59] S. Sheehy,et al. The contribution of cellular mechanotransduction to cardiomyocyte form and function , 2012, Biomechanics and Modeling in Mechanobiology.
[60] F. Tubach,et al. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome. , 2010, Archives of cardiovascular diseases.
[61] Peter D Yurchenco,et al. Laminin assembles into separate basement membrane and fibrillar matrices in Schwann cells. , 2002, Journal of cell science.